Biohaven Ltd. (BHVN)
| Market Cap | 1.94B +24.0% |
| Revenue (ttm) | n/a |
| Net Income | -586.84M |
| EPS | -4.48 |
| Shares Out | 151.04M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,753,081 |
| Open | 13.41 |
| Previous Close | 13.14 |
| Day's Range | 12.63 - 13.51 |
| 52-Week Range | 7.48 - 18.57 |
| Beta | 3.17 |
| Analysts | Buy |
| Price Target | 21.27 (+65.27%) |
| Est. Earnings | Nov 5, 2026 |
About BHVN
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for BHVN stock is "Buy." The 12-month stock price target is $21.27, which is an increase of 65.27% from the latest price.
News
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeuti...
Citi views Xenon study pause as positive for Biohaven
Citi analyst Samantha Semenkow views Xenon Pharmaceuticals’ (XENE) voluntarily pause in new enrollment for its ongoing trials for major depressive disorder and bipolar depression as favorable for Bioh...
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN)
Biohaven shares gave up nearly 15% in a single session on September 10, 2026 following the FDA's partial clinical hold on new-patient enrollment in the BHV-7000/opakalim epilepsy trials NEW YORK, Sept...
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
Biohaven clinical hold adds level of uncertainty, says H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao keeps a Neutral rating on Biohaven (BHVN) with a $10 price target after the FDA issued a partial clinical hold, pausing new patient enrollment across…
Impact of Biohaven’s partial FDA hold ‘manageable,’ says Raymond James
Biohaven’s (BHVN) partial FDA hold on new enrollment for BHV-7000 has driven a 15% selloff, but the setback appears manageable given SK Bio’s prior awareness and continued commitment to its…
Biohaven down 15% after FDA puts partial clinical hold on BHV-7000 program
In a regulatory filing earlier, Biohaven (BHVN) provided updates to the BHV-7000 program. The company stated: In January 2024, we completed our End-of-Phase 2 meeting with the U.S. Food and…
US FDA pauses new enrollment in Biohaven's epilepsy drug trials
Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials of its experimental epilepsy drug after rodent findings, sending its shares down ...
Biohaven downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Biohaven (BHVN) to Sector Perform from Outperform with a price target of $19, down from $23. With the shares up 100% since the lows earlier this year,…
H.C. Wainwright says Biohaven license agreement buys time, ‘not a solution’
H.C. Wainwright notes that Biohaven (BHVN) announced a global licensing and collaboration agreement granting SK Biopharmaceuticals an exclusive worldwide license to its Kv7 ion channel platform, led b...
Biohaven price target lowered to $30 from $50 at Raymond James
Raymond James lowered the firm’s price target on Biohaven (BHVN) to $30 from $50 and keeps a Strong Buy rating on the shares. Monetizing Opakalim extends the company’s cash runway…
Biohaven to receive $400M in SK Biopharmaceuticals licensing, collaboration pact
Biohaven (BHVN) and SK Biopharmaceuticals announced a strategic global licensing and collaboration agreement under which SK Biopharmaceuticals will obtain an exclusive worldwide license to Biohaven’s ...
Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million
Biohaven has entered into a licensing agreement with South Korean drug maker SK Biopharmaceuticals for Biohaven's epilepsy drug platform, including Opakalim, for up to $795 million, the com...
Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
SK Biopharmaceuticals to provide upfront and milestone payments related to the Kv7 platform up to $795 million, along with tiered royalties to Biohaven ranging from the mid-teens to low twenties on U....
Federal Court Enters Judgment Confirming RA Capital and Avilar Therapeutics Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Formalizing $4 Million Award to Biohaven and Yale University
NEW HAVEN, Conn., Aug. 25, 2026 /PRNewswire/ -- Biohaven Ltd.
Biohaven price target raised to $19 from $18 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Biohaven (BHVN) to $19 from $18 and keeps an Overweight rating on the shares. Key pipeline programs remain on track, says the…
Biohaven price target raised to $23 from $22 at RBC Capital
RBC Capital raised the firm’s price target on Biohaven (BHVN) to $23 from $22 and keeps an Outperform rating on the shares. The firm cites the company’s better-than-expected Q2 results,…
Biohaven reports Q2 EPS (78c), consensus (61c)
Cash, cash equivalents, marketable securities and restricted cash as of June 30, 2026, totaled approximately $270.5M. Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven (BHVN), comment...
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed, Phase 3 trial underway Positive clinical...
Biohaven Quarterly report: Q2 2026
Biohaven has published its Q2 2026 quarterly earnings report on August 10, 2026.
Biohaven Earnings release: Q2 2026
Biohaven released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors
Infinitum founder and Groq board director brings frontier AI and technology-investing expertise to Biohaven as the company advances AI-enabled approaches to drug development NEW HAVEN, Conn., Aug. 6, ...